Topical Ruxolitinib for Alopecia Areata: Current Evidence and Future Perspectives

Abstract

Alopecia areata (AA) is an immune-mediated, non-scarring hair-loss disorder in which dysregulation of the JAK–STAT pathway plays an important role in follicular inflammation. Ruxolitinib is a selective Janus kinase 1/2 (JAK1/JAK2) inhibitor that suppresses key inflammatory signaling pathways, particularly interferon-γ and interleukin-15, thereby reducing T-cell activation and helping restore hair-follicle immune privilege. Topical ruxolitinib 1.5% cream has been developed to provide targeted local immunomodulation while minimizing the systemic adverse effects associated with oral JAK inhibitors. Its topical formulation achieves low systemic exposure while enhancing drug delivery through the skin toward affected follicles. In alopecia areata, topical JAK inhibitors may be beneficial particularly in localized patchy disease, although reported clinical responses remain variable because adequate drug penetration to the deep hair bulb can be limited. Dermoscopic evaluation is useful for objectively monitoring treatment response through changes in disease-activity markers, such as black dots, and the appearance of signs of follicular recovery. Therefore, clinical and dermoscopic assessment of topical ruxolitinib may provide valuable information regarding its efficacy, response pattern, and potential role in the treatment of patchy AA.